StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Alnylam Pharma (ALNY) Gains 22% on Patisiran Phase 3 Trial Success
September 20, 2017 7:53 AM
Alnylam Pharma (NASDAQ: ALNY) shares are trading up 22% in ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Momentum Movers
Trader Talk
Next Articles
Alnylam Pharmaceuticals (ALNY) PT Raised to $125 at Needham & Company
September 20, 2017 3:20 PM
Alnylam Pharmaceuticals (ALNY) PT Raised to $83 at Stifel
September 20, 2017 1:41 PM
Alnylam Pharmaceuticals (ALNY) PT Raised to $117 at Cowen; 'Best-Case Scenario'
September 20, 2017 12:36 PM
Alnylam Pharmaceuticals (ALNY) PT Raised to $116 at Piper Jaffray
September 20, 2017 11:39 AM
Alnylam Pharma (ALNY) Adds to Gains; Shares up 40%
September 20, 2017 10:23 AM
Ionis Pharma (IONS) Sinks on Alnylam (ALNY) Patisiran Success
September 20, 2017 7:36 AM
Sanofi, Alnylam Pharmaceuticals (ALNY) Announces APOLLO Phase 3 Study of Patisiran Met Primary Efficacy Endpoint and All Secondary Endpoints
September 20, 2017 7:02 AM
Sanofi (SNY) and Alnylam (ALNY) APOLLO Phase 3 Study of Patisiran in hATTR Meets Primary, Secondary Endpoints
September 20, 2017 7:01 AM
Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
September 20, 2017 7:00 AM
